Probiotics, secretory IgA and inflammation

Patent metadata

Field	Value
Publication number	US-9822167-B2
Application number	US-200913000666-A
Country	US
Kind code	B2
Filing date	Jun 16, 2009
Priority date	Jun 24, 2008
Publication date	Nov 21, 2017
Grant date	Nov 21, 2017

Abstract

The present invention relates generally to the field of nutrition, health and wellness. In particular the present invention relates to probiotics and ways to increase their effectiveness. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a use of a composition comprising SIgA and at least one probiotic for the preparation of a product to treat or prevent inflammation is disclosed.

First claim

The invention claimed is:

1. A method for treating inflammation, the method comprising:
administering a therapeutically-effective amount of a composition comprising an isolated secretory IgA (SIgA) of 0.0001 mg to 10 mg per daily dose and at least one probiotic of 10 2 to 10 10 cells per daily dose, wherein the SIgA and the at least one probiotic are associated by a chemical bond as complexes in the composition, to a subject having the inflammation.

2. The method of claim 1 wherein the composition generates, improves or reinforces homeostasis and oral tolerance.

3. The method of claim 1 wherein the at least one probiotic is selected from the group consisting of Bifidobacterium, Lactobacillus, Streptococcus, Saccharomyces and mixtures thereof.

4. The method of claim 1 , wherein the composition is selected from the group consisting of a food product, an animal food product and a pharmaceutical composition.

5. The method of claim 1 , wherein the subject is a human.

6. The method of claim 1 , wherein the composition controls and/or alleviates inflammatory reaction.

7. The method of claim 1 , wherein the composition comprises at least one other kind of other food grade bacteria.

8. The method of claim 1 , wherein the composition further contains at least one prebiotic.

9. The method of claim 1 wherein the at least one probiotic is selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus salivarius, Enterococcus faecium, Saccharomyces boulardii, Lactobacillus reuteri and mixtures thereof.

10. The method of claim 1 , wherein the composition comprises at least one other kind of other food grade bacteria selected from the group consisting of lactic acid bacteria, bifidobacteria, enterococci and mixtures thereof.

11. The method of claim 1 , wherein the at least one probiotic is selected from the group consisting of Lactobacillus rhamnosus NCC4007 (LPR) and Bifidobacterium lactis NCC2818 (BL818).

12. The method of claim 1 , wherein the SIgA and the at least one probiotic micro-organism are present in a stoichiometric ratio of at least 10:1.

Assignees

• Benyacoub Jalil
• Corthesy Blaise
• Blum-Sperisen Stephanie
• Favre Laurent
• Nestec Sa

Inventors

• Benyacoub Jalil
• Corthesy Blaise
• Blum-Sperisen Stephanie
• Favre Laurent

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title